Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry

Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an i...

Descripción completa

Detalles Bibliográficos
Autores: Musto, Pellegrino, Salmanton-García, Jon, Sgherza, Nicola, Bergantim, Rui, Farina, Francesca, Glenthøj, Andreas, Espigado Tocino, Ildefonso, Pagano, Livio
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/175727
Acceso en línea:https://hdl.handle.net/11441/175727
https://doi.org/10.1002/hon.3240
Access Level:acceso abierto
Palabra clave:COVID‐19
Hematological malignancy
Multiple myeloma
SARS‐CoV‐2
id ES_e960adf7053d22457218f9bb606b287c
oai_identifier_str oai:idus.us.es:11441/175727
network_acronym_str ES
network_name_str España
repository_id_str
spelling Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registryMusto, PellegrinoSalmanton-García, JonSgherza, NicolaBergantim, RuiFarina, FrancescaGlenthøj, AndreasEspigado Tocino, IldefonsoPagano, LivioCOVID‐19Hematological malignancyMultiple myelomaSARS‐CoV‐2Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 109/L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.WileyMedicina2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/175727https://doi.org/10.1002/hon.3240reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésHematological Oncology, 41 (1), e3240.https://onlinelibrary.wiley.com/doi/10.1002/hon.3240info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1757272026-06-17T12:51:07Z
dc.title.none.fl_str_mv Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
title Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
spellingShingle Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
Musto, Pellegrino
COVID‐19
Hematological malignancy
Multiple myeloma
SARS‐CoV‐2
title_short Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
title_full Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
title_fullStr Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
title_full_unstemmed Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
title_sort Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
dc.creator.none.fl_str_mv Musto, Pellegrino
Salmanton-García, Jon
Sgherza, Nicola
Bergantim, Rui
Farina, Francesca
Glenthøj, Andreas
Espigado Tocino, Ildefonso
Pagano, Livio
author Musto, Pellegrino
author_facet Musto, Pellegrino
Salmanton-García, Jon
Sgherza, Nicola
Bergantim, Rui
Farina, Francesca
Glenthøj, Andreas
Espigado Tocino, Ildefonso
Pagano, Livio
author_role author
author2 Salmanton-García, Jon
Sgherza, Nicola
Bergantim, Rui
Farina, Francesca
Glenthøj, Andreas
Espigado Tocino, Ildefonso
Pagano, Livio
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
dc.subject.none.fl_str_mv COVID‐19
Hematological malignancy
Multiple myeloma
SARS‐CoV‐2
topic COVID‐19
Hematological malignancy
Multiple myeloma
SARS‐CoV‐2
description Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 109/L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/175727
https://doi.org/10.1002/hon.3240
url https://hdl.handle.net/11441/175727
https://doi.org/10.1002/hon.3240
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Hematological Oncology, 41 (1), e3240.
https://onlinelibrary.wiley.com/doi/10.1002/hon.3240
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423021930840064
score 15,812455

Similares en LA Referencia